1834 related articles for article (PubMed ID: 9269956)
1. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
2. Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802.
Mousa SA; Olson RE; Bozarth JM; Lorelli W; Forsythe MS; Racanelli A; Gibbs S; Schlingman K; Bozarth T; Kapil R; Wityak J; Sielecki TM; Wexler RR; Thoolen MJ; Slee A; Reilly TM; Anderson PS; Friedman PA
J Cardiovasc Pharmacol; 1998 Aug; 32(2):169-76. PubMed ID: 9700976
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.
Moritani Y; Sato K; Shigenaga T; Hisamichi N; Ichihara M; Akamatsu S; Suzuki Ki; Nii T; Kaku S; Kawasaki T; Matsumoto Y; Inagaki O; Tomioka K; Yanagisawa I
Eur J Pharmacol; 2002 Mar; 439(1-3):43-52. PubMed ID: 11937091
[TBL] [Abstract][Full Text] [Related]
4. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
[TBL] [Abstract][Full Text] [Related]
6. Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity.
Mousa SA; Forsythe M; Lorelli W; Bozarth J; Xue CB; Wityak J; Sielecki TM; Olson RE; DeGrado W; Kapil R; Hussain M; Wexler R; Thoolen MJ; Reilly TM
Coron Artery Dis; 1996 Oct; 7(10):767-74. PubMed ID: 8970768
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
[TBL] [Abstract][Full Text] [Related]
8. Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: activation by ADP and a thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists.
Cook NS; Zerwes HG; Tapparelli C; Powling M; Singh J; Metternich R; Hagenbach A
Thromb Haemost; 1993 Sep; 70(3):531-9. PubMed ID: 8259560
[TBL] [Abstract][Full Text] [Related]
9. The in vitro and in vivo pharmacological profiles of a platelet glycoprotein IIb/IIIa antagonist, NSL-9403.
Katada J; Takiguchi Y; Muramatsu M; Fujiyoshi T; Uno I
Thromb Res; 1997 Oct; 88(1):27-40. PubMed ID: 9336871
[TBL] [Abstract][Full Text] [Related]
10. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
Kawano KI; Hokamura K; Kondo K; Ikeda Y; Suzuki Y; Umemura K
Eur J Pharmacol; 2001 Apr; 417(3):217-22. PubMed ID: 11334853
[TBL] [Abstract][Full Text] [Related]
11. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
[TBL] [Abstract][Full Text] [Related]
12. Effect of aspirin on platelet desaggregation induced by SR121566, a potent GP-IIb/IIIa antagonist.
Savi P; Bernat A; Lalé A; Roque C; Zamboni G; Herbert JM
Platelets; 2000 Feb; 11(1):43-8. PubMed ID: 10938881
[TBL] [Abstract][Full Text] [Related]
13. The anti-platelet and anti-thrombotic effects of FK633, a peptide-mimetic GPIIB/IIIA antagonist.
Aoki T; Cox D; Senzaki K; Seki J; Tanaka A; Takasugi H; Motoyama Y
Thromb Res; 1996 Feb; 81(4):439-50. PubMed ID: 8907293
[TBL] [Abstract][Full Text] [Related]
14. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
Azzam K; Cissé-Thiam M; Drouet L
Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GP IIb/IIIa antagonist, in rabbits: comparison with clopidogrel and aspirin.
Hoffmann P; Bernat A; Savi P; Herbert JM
J Cardiovasc Pharmacol; 1997 Sep; 30(3):360-6. PubMed ID: 9300321
[TBL] [Abstract][Full Text] [Related]
16. Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth. An ex vivo capillary perfusion chamber study in the guinea pig.
André P; Arbeille B; Drouet V; Hainaud P; Bal dit Sollier C; Caen JP; Drouet LO
Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):56-63. PubMed ID: 8548427
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749).
Nicholson NS; Panzer-Knodle SG; Salyers AK; Taite BB; King LW; Miyano M; Gorczynski RJ; Williams MH; Zupec ME; Tjoeng FS
J Pharmacol Exp Ther; 1991 Mar; 256(3):876-82. PubMed ID: 2005585
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist.
Damiano BP; Mitchell JA; Giardino E; Corcoran T; Haertlein BJ; de Garavilla L; Kauffman JA; Hoekstra WJ; Maryanoff BE; Andrade-Gordon P
Thromb Res; 2001 Oct; 104(2):113-26. PubMed ID: 11672755
[TBL] [Abstract][Full Text] [Related]
19. XV454, a novel nonpeptide small-molecule platelet GIIb/IIIa antagonist with comparable platelet alpha(IIb)beta3-binding kinetics to c7E3.
Mousa SA; Forsythe M; Bozarth J; Youssef A; Wityak J; Olson R; Sielecki T
J Cardiovasc Pharmacol; 1998 Nov; 32(5):736-44. PubMed ID: 9821847
[TBL] [Abstract][Full Text] [Related]
20. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress.
Uemura T; Kawasaki T; Taniguchi M; Moritani Y; Hayashi K; Saito T; Takasaki J; Uchida W; Miyata K
Br J Pharmacol; 2006 May; 148(1):61-9. PubMed ID: 16520742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
